300 related articles for article (PubMed ID: 23015379)
61. Cost-Effectiveness Analysis of the Implementation of Cryptococcal Antigen Lateral Flow Assay for the Diagnosis of Cryptococcal Meningitis in Symptomatic People Living With Human Immunodeficiency Virus in Brazil.
Vianna CMM; Mosegui GBG
Value Health Reg Issues; 2022 May; 29():53-59. PubMed ID: 34801886
[TBL] [Abstract][Full Text] [Related]
62. Evaluation of the initial 12 months of a routine cryptococcal antigen screening program in reduction of HIV-associated cryptococcal meningitis in Uganda.
Enock K; Julius K; Griffith BC; Abila DB; Rutakingirwa MK; Kasibante J; Kandole KT; Kwizera R; Semeere A; Meya DB
BMC Health Serv Res; 2022 Mar; 22(1):301. PubMed ID: 35246128
[TBL] [Abstract][Full Text] [Related]
63. Serum cyrptococcal antigen: diagnostic value in the diagnosis of AIDS-related cryptococcal meningitis.
Asawavichienjinda T; Sitthi-Amorn C; Tanyanont V
J Med Assoc Thai; 1999 Jan; 82(1):65-71. PubMed ID: 10087741
[TBL] [Abstract][Full Text] [Related]
64. Long-term follow-up and survival of antiretroviral-naive patients with cryptococcal meningitis in the pre-antiretroviral therapy era, Gauteng Province, South Africa.
Park BJ; Shetty S; Ahlquist A; Greenbaum A; Miller JL; Motsi A; McCarthy K; Govender N;
Int J STD AIDS; 2011 Apr; 22(4):199-203. PubMed ID: 21515751
[TBL] [Abstract][Full Text] [Related]
65. Discontinuation of highly active antiretroviral therapy leads to cryptococcal meningitis/choroiditis in an AIDS patient.
Chronister CL
Optometry; 2006 Sep; 77(9):438-45. PubMed ID: 16939885
[TBL] [Abstract][Full Text] [Related]
66. [Cryptococcal neuromeningitidis in HIV-infected patients in Bangui, in the era of antiretroviral treatment].
Gbangba-Ngai E; Fikouma V; Mossoro-Kpinde CD; Tekpa G; Ouavene JO; Yangba Mongba DS; Mbelesso P
Bull Soc Pathol Exot; 2014 May; 107(2):106-9. PubMed ID: 24570116
[TBL] [Abstract][Full Text] [Related]
67. Comparison of cryptococcal antigenemia between antiretroviral naïve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia.
Beyene T; Woldeamanuel Y; Asrat D; Ayana G; Boulware DR
PLoS One; 2013; 8(10):e75585. PubMed ID: 24124498
[TBL] [Abstract][Full Text] [Related]
68. Cryptococcal antigenemia and associated risk factors among ART-naïve and ART-experienced HIV-infected peoples at selected health institutions of Mekelle, Northern Ethiopia.
Hailu K; Niguse S; Hagos K; Abdulkader M
Microbiologyopen; 2019 Jun; 8(6):e00746. PubMed ID: 30277315
[TBL] [Abstract][Full Text] [Related]
69. New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis.
Jackson A; van der Horst C
Curr HIV/AIDS Rep; 2012 Sep; 9(3):267-77. PubMed ID: 22763808
[TBL] [Abstract][Full Text] [Related]
70. Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study.
Wajanga BM; Kalluvya S; Downs JA; Johnson WD; Fitzgerald DW; Peck RN
J Int AIDS Soc; 2011 Oct; 14():48. PubMed ID: 21988905
[TBL] [Abstract][Full Text] [Related]
71. [Prevalence and factors associated with cryptococcal antigenemia in HIV-infected patients in Cotonou/Benin].
Ogouyèmi-Hounto A; Zannou DM; Ayihounton G; Ahouada C; Azon-Kouanou A; Acakpo J; Sissinto Savi de Tove Y; Kinde Gazard D
J Mycol Med; 2016 Dec; 26(4):391-397. PubMed ID: 27641486
[TBL] [Abstract][Full Text] [Related]
72. Outcomes of Reflex Cryptococcal Antigen (CrAg) Screening in Human Immunodeficiency Virus (HIV)-Positive Patients With CD4 Counts of 100-200 Cells/µL in Botswana.
Tenforde MW; Milton T; Rulaganyang I; Muthoga C; Tawe L; Chiller T; Greene G; Jordan A; Williams CG; Owen L; Leeme TB; Boose A; Ngidi J; Mine M; Jarvis JN
Clin Infect Dis; 2021 May; 72(9):1635-1638. PubMed ID: 32604411
[TBL] [Abstract][Full Text] [Related]
73. Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia.
Kapoor SW; Magambo KA; Kalluvya SE; Fitzgerald DW; Peck RN; Downs JA
AIDS; 2015 Nov; 29(18):2473-8. PubMed ID: 26372487
[TBL] [Abstract][Full Text] [Related]
74. Cryptococcal meningitis in HIV-infected patients: a longitudinal study in Cambodia.
Espié E; Pinoges L; Balkan S; Chanchhaya N; Molfino L; Narom P; Pujades-Rodríguez M
Trop Med Int Health; 2010 Nov; 15(11):1375-81. PubMed ID: 20868415
[TBL] [Abstract][Full Text] [Related]
75. Cryptococcal meningitis.
Jones GA; Nathwani D
Br J Hosp Med; 1995 Nov 1-14; 54(9):439-45. PubMed ID: 8564179
[TBL] [Abstract][Full Text] [Related]
76. Prognostic markers in AIDS-related cryptococcal meningitis.
Majumder S; Mandal SK; Bandyopadhyay D
J Assoc Physicians India; 2011 Mar; 59():152-4. PubMed ID: 21751623
[TBL] [Abstract][Full Text] [Related]
77. No association of cryptococcal antigenemia with poor outcomes among antiretroviral therapy-experienced HIV-infected patients in Addis Ababa, Ethiopia.
Smitson CC; Tenna A; Tsegaye M; Alemu AS; Fekade D; Aseffa A; Blumberg HM; Kempker RR
PLoS One; 2014; 9(1):e85698. PubMed ID: 24465651
[TBL] [Abstract][Full Text] [Related]
78. Magnitude of Cryptococcal Antigenemia among HIV Infected Patients at a Referral Hospital, Northwest Ethiopia.
Derbie A; Ayalew W; Mekonnen D; Alemu M; Mulugeta Y
Ethiop J Health Sci; 2018 Jul; 28(4):369-374. PubMed ID: 30607049
[TBL] [Abstract][Full Text] [Related]
79. Clinical and laboratory features of cryptococcal meningitis in HIV-AIDS patients.
Deo S
J Assoc Physicians India; 1995 Oct; 43(10):724. PubMed ID: 8773019
[No Abstract] [Full Text] [Related]
80. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis.
Powderly WG; Cloud GA; Dismukes WE; Saag MS
Clin Infect Dis; 1994 May; 18(5):789-92. PubMed ID: 8075272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
